Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Osteoporos Rep. 2012 Mar;10(1):56-63. doi: 10.1007/s11914-011-0091-y.

Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.

Author information

1
Park Nicollet Health Services, Division of Health Policyand Management, University of Minnesota, Minneapolis, MN, USA. scho0600@umn.edu

Abstract

Monitoring of drug therapies to prevent fractures is controversial. Measurement of bone turnover markers has the potential to identify those with a suboptimal response to fracture prevention medication within a few months of its commencement. However, given the imprecision of currently commercially available assays of bone turnover markers, many individual persons who are “suboptimal medication responders” are likely to be misclassified as “adequate responders” or vice versa, depending on the cut point chosen to define suboptimal and adequate response. Before bone turnover markers can be recommended for routine use in clinical practice to monitor fracture prevention therapies, three advances are needed: 1) bone marker assays with better precision; 2) research establishing optimal cut points of bone marker levels to distinguish “suboptimal responders” from “adequate responders”; and 3) research establishing the incremental fracture reduction benefit from clinical interventions for “suboptimal responders” identified from bone marker measurements.

PMID:
22286411
PMCID:
PMC4004108
DOI:
10.1007/s11914-011-0091-y
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center